Sinusitis Exclusion From Nasal Decongestant Labels Is Unsupported – Pfizer
This article was originally published in The Tan Sheet
Executive Summary
Physician intervention could be the only recourse for consumers suffering from sinusitis if FDA were to remove the indication from OTC product labels, according to Pfizer Consumer Healthcare
You may also be interested in...
Sinusitis Indication Removed From OTC Decongestant Monograph
Marketers of OTC nasal decongestants have an April 11, 2007 deadline to remove references to the indication "sinusitis" from product labeling in order to comply with a monograph amendment
Sinusitis Indication Removed From OTC Decongestant Monograph
Marketers of OTC nasal decongestants have an April 11, 2007 deadline to remove references to the indication "sinusitis" from product labeling in order to comply with a monograph amendment
Sinusitis Indication Removed From OTC Decongestant Monograph
Marketers of OTC nasal decongestants have an April 11, 2007 deadline to remove references to the indication "sinusitis" from product labeling in order to comply with a monograph amendment